Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Cleve Clin J Med. 2009 Dec;76(12):707-14. doi: 10.3949/ccjm.76a.09116.
Prasugrel (Effient) has been approved for reducing the risk of thrombotic complications in patients with acute coronary syndromes who are to undergo percutaneous coronary intervention. In a large clinical trial (N Engl J Med 2007; 357:2001-2005), prasugrel was superior to clopidogrel (Plavix), another drug of its class, in this situation. However, bleeding complications were more frequent with prasugrel, and so this drug should be avoided in patients at higher risk of bleeding.
普拉格雷（依非乐）已获批准用于降低行经皮冠状动脉介入治疗的急性冠脉综合征患者的血栓并发症风险。在一项大型临床试验（N Engl J Med 2007; 357:2001-2005）中，普拉格雷在这种情况下优于其同类药物氯吡格雷（波立维）。然而，普拉格雷的出血并发症更为常见，因此应避免在出血风险较高的患者中使用该药。
